KR102214461B1 - Apparatus for testing drug-responsibility - Google Patents

Abstract

The present invention relates to a reaction chamber part having a cavity for accommodating a sample, a plurality of microchannels disposed to be spaced apart from each other under the cavity, and transferring a drug reacting with the sample, the sample and the plurality of microfluidics It provides a drug reactivity test device, which is interposed between flow paths and includes a permeable portion for transmitting the drug toward the specimen.

Description

Apparatus for testing drug-responsibility

Embodiments of the present invention relate to a drug reactivity testing device, and more particularly, to a drug reactivity testing device capable of simultaneously testing the reactivity of a sample to various drugs within a single device.

Along with the increase in the elderly population, cancer patients are increasing gradually due to various congenital and acquired causes. Despite the recent advances in modern medicine, cancer still remains one of the challenges that modern medicine has to solve.

In general, cancer treatment methods include surgical surgery and radiation therapy. In addition to these treatment methods, drug treatment is also very important. Therefore, many countries around the world are investing heavily in the development of new drugs to conquer cancer, and at the same time, they are focusing their efforts on the prescription of drugs suitable for patients.

Meanwhile, since there are differences in genetic characteristics and lifestyle habits for each patient, it is not easy to prescribe a drug suitable for a specific patient. Therefore, recently, while culturing patient-derived cells, a plurality of anticancer agents to be tested are exposed to patient-derived cells to test reactivity, and then the optimal drug is selected.

However, in most cases of patient-derived cells, the viability of the cells decreases rapidly over time, so it is important to create a cell-friendly environment and conduct the experiment as quickly as possible.

In the conventional case, patient-derived cells were extracted, subcultured to increase the number of cells, and then the proliferated cells were tested for drug reactivity. At this time, if the cells are not proliferated properly, a sufficient number of cells may not be obtained for the test, and the characteristics of the patient-derived cells change during the subculture, resulting in errors in the test results.

An object of the present invention is to provide a drug reactivity testing device capable of simultaneously testing the reactivity of a specimen with respect to various drugs within a single device, in order to solve various problems including the above problems. However, these problems are exemplary, and the scope of the present invention is not limited thereby.

According to an aspect of the present invention, a reaction chamber unit having a cavity for accommodating a sample, a plurality of microchannels disposed to be spaced apart from each other under the cavity, and transferring a drug reacting with the sample, and the sample and the A drug reactivity test apparatus is provided, which is interposed between a plurality of microchannels and includes a permeable portion for transmitting the drug toward the specimen.

A cover portion may be further provided in the cavity to cover the specimen and the transmission portion.

The cover part may include an extracellular matrix (ECM) mimicking material.

An inflow chamber part for introducing the drug into the plurality of micro-channels may be further provided.

The inflow chamber part may include a plurality of individual chamber parts connected to each of the plurality of micro flow paths.

A discharge chamber part for discharging the drug from the plurality of micro-channels may be further provided.

The plurality of micro-channels include a first micro-channel and a second micro-channel, and the first drug transported through the first micro-channel may be different from the second drug transported through the second micro-channel. I can.

The plurality of micro-channels include a first micro-channel and a second micro-channel, and the first drug transferred through the first micro-channel may have a different concentration than the second drug transferred through the second micro-channel. I can.

Each of the plurality of fine flow paths may have the same length and width.

Each of the plurality of micro-channels may simultaneously transport the drug.

The transmission part may deliver the drug to regions partitioned corresponding to each of the plurality of micro-channels of the cavity.

The transmission unit may include a plurality of individual transmission units for delivering the drug to each of the divided regions.

The permeable part may include a membrane for partially passing the drug through the plurality of microchannels.

The specimen may contain cells.

The drug may include an anticancer agent.

According to an embodiment of the present invention made as described above, it is possible to simultaneously test the reactivity of a specimen to various drugs within a single device.

In addition, a relatively small number of cells can be tested without cell proliferation.

In addition, it is possible to minimize the decrease in cell viability through rapid testing.

In addition, customized drug prescription for each patient is possible.

Of course, the scope of the present invention is not limited by these effects.

1 is a plan view schematically showing an apparatus for testing drug reactivity according to an embodiment of the present invention.
FIG. 2 is an enlarged plan view of a part of the drug reactivity test apparatus of FIG. 1.
3 is a cross-sectional view taken along line III-III' of FIG. 2.
4 is a plan view schematically showing an apparatus for testing drug reactivity according to another embodiment of the present invention.
5 is an image showing a result of injecting a dye into the drug reactivity test apparatus according to an embodiment of the present invention.
6 is an image showing a result of injecting a drug into the drug reactivity test apparatus according to an embodiment of the present invention.

Since the present invention can apply various transformations and have various embodiments, specific embodiments are illustrated in the drawings, and will be described in detail in the detailed description. However, this is not intended to limit the present invention to a specific embodiment, it is to be understood to include all conversions, equivalents, and substitutes included in the spirit and scope of the present invention. In describing the present invention, when it is determined that a detailed description of a related known technology may obscure the subject matter of the present invention, a detailed description thereof will be omitted.

Terms such as first and second used in this specification may be used to describe various elements, but the elements should not be limited by terms. The terms are only used for the purpose of distinguishing one component from another component.

Hereinafter, embodiments according to the present invention will be described in detail with reference to the drawings, and in the description with reference to the drawings, substantially identical or corresponding components are given the same reference numbers, and redundant descriptions thereof will be omitted. do. In the drawings, the thicknesses are enlarged to clearly express various layers and regions. In addition, in the drawings, the thicknesses of some layers and regions are exaggerated for convenience of description.

1 is a plan view schematically showing an apparatus for testing drug reactivity according to an embodiment of the present invention.

Referring to FIG. 1, a drug reactivity test apparatus 10 according to an embodiment of the present invention includes a reaction chamber unit 100, a plurality of microchannels 210, 220, 230, 240, 250, ??), and a transmission unit. It has 300.

The reaction chamber unit 100 includes a cavity (not shown) for accommodating a specimen to be tested by the drug reactivity test apparatus 10. At this time, the specimen includes cells, and may include, for example, patient-derived cells or various other experimental cells.

In an embodiment, the reaction chamber unit 100 may be an open well having a bottom area of approximately 200 mm ² . Therefore, in the reaction chamber unit 100, various shapes and sizes ranging from a cell solution dissociated at the level of a single cell to a relatively large cell aggregate, organoid, and tissue. Samples of can be received as a specimen.

In FIG. 1, the reaction chamber unit 100 is shown to have a rectangular shape, but is not limited thereto, and may be designed to have an appropriate shape in consideration of the shape of a specimen accommodated in the reaction chamber unit 100.

The cavity located inside the reaction chamber unit 100 may be formed similar to the outer shape of the reaction chamber unit 100, but is not limited thereto and may have a shape different from the outer shape of the reaction chamber unit 100. In addition, it may be designed to have a shape similar to that of the specimen accommodated in the reaction chamber unit 100.

This cavity not only provides a space for accommodating the specimen, but also provides a space for a reaction between the specimen and the drug. Therefore, the reaction result between the sample and the drug can be confirmed by introducing the drug to be reacted with the sample into the cavity.

A plurality of fine flow paths 210, 220, 230, 240, 250, ?? are connected to the cavity. The plurality of micro-channels 210, 220, 230, 240, 250, ?? are disposed to be spaced apart from each other, and serve to transport a drug to be reacted with the specimen toward the cavity.

The plurality of micro-channels 210, 220, 230, 240, 250, ?? may be formed using micro fluidic channel technology. The plurality of micro-channels 210, 220, 230, 240, 250, ??) have a width or diameter of several µm to hundreds of µm, and may be designed to be appropriate values according to the fluidity and flow rate of the drug to be transferred.

For convenience of description, the structure and function will be described in detail with reference to the first to fifth microchannels 210, 220, 230, 240 and 250 marked with reference numerals. Accordingly, the description of the micro-channels below may be equally applied to the remaining flow paths other than the first to fifth micro-channels 210, 220, 230, 240, and 250. This is also the same in the description with reference to FIGS. 2 to 6.

Micro flow paths 210, 220, 230, 240, 250 are reaction flow paths 211, 221, 231, 241, 251 and connection flow paths 212, 222, 232, 242 (252) may be included. At this time, the reaction channels 211, 221, 231, 241, and 251 are portions located directly under the reaction chamber unit 100 in which a reaction between the specimen and the drug occurs, and the connection channels 212, 222, and The 232, 242, 252 are connected to the reaction flow paths 211, 221, 231, 241, 251 and are located outside the reaction chamber unit 100.

The inlet chamber 80 is connected to the connection flow path 212, 222, 232, 242, 252. Specifically, the connection flow paths 212, 222, 232, 242, 252 connected to the inflow chamber 80 extend to the reaction flow paths 211, 221, 231, 241, 251.

The inlet chamber unit 80 is a portion for introducing a drug into each of the connection flow paths 212, 222, 232, 242, 252, and a drug is injected into the inlet chamber unit 80 using a dropper or a syringe, The drug is temporarily stored in the inflow chamber unit 80 before flowing into the connection flow paths 212, 222, 232, 242, 252.

In one embodiment, the inlet chamber unit 80 may include a plurality of individual chamber units 81, 82, 83, 84 and 85. For example, in the first connection flow path 212, the second connection flow path 222, the third connection flow path 232, the fourth connection flow path 242, and the fifth connection flow path 252, each of the first inlet chamber portions 81 ), the second inlet chamber portion 82, the third inlet chamber portion 83, the fourth inlet chamber portion 84, and the fifth inlet chamber portion 85 may be connected. As a result, different drugs can be simultaneously introduced for each of the connection channels, and thus, it may be very effective when there are multiple types of drugs or experimental conditions to check the reactivity with the specimen.

The drug injected into the inlet chamber unit 80 and passed through the connection passages 212, 222, 232, 242, 252 flows into the reaction passages 211, 221, 231, 241, 251 and enters the reaction chamber unit 100 ). After that, a part of the drug that has reached the reaction chamber unit 100 reacts with the sample accommodated in the reaction chamber unit 100, and the remaining drugs that have not reacted with the sample are the reaction channels 211, 221, 231, 241, 251 It is discharged to the discharge chamber 90 through the.

The discharge chamber unit 90 is connected to the reaction flow paths 211, 221, 231, 241, 251 to discharge the drug passing through the reaction flow paths 211, 221, 231, 241, 251, and for this purpose Separate discharge flow paths (not shown) may be disposed between the fields 211, 221, 231, 241, 251 and the discharge chamber unit 90.

Since it is a space for discharging the drug after the test is finished, as shown in FIG. 1, the discharge chamber 90 may be designed as one, but is not limited thereto. That is, when there is a drug that can be reused or must be disposed of separately, the discharge chamber unit 90 may be designed to include a plurality of individual chamber units, similar to the inflow chamber unit 80.

On the other hand, the plurality of micro-channels 210, 220, 230, 240, 250, respectively, so that the drug introduced into the plurality of micro-channels 210, 220, 230, 240, 250 can be transferred under approximately the same flow conditions. Can have approximately the same length and width. That is, by forming the flow rate and flow distance of each of the micro flow paths to be constant, the drug passing through each of the micro flow paths reaches the reaction chamber unit 100 at a constant flow rate. Reactivity can be checked at the same time.

In order to form the plurality of micro-channels 210, 220, 230, 240, 250 to have approximately the same length and width, the plurality of micro-channels 210, 220, 230, 240, 250 is a reaction chamber unit ( 100) can be arranged approximately radially around the center. By doing so, it is possible to connect as many microchannels as possible to the reaction chamber unit 100.

In this way, since several drugs can be tested at the same time in a single experiment, test results can be obtained quickly even when there is a concern about contamination or loss of a sample or when it is difficult to collect a sample.

In one embodiment, the specimen may contain cells of a cancer patient, and the drug reaction may be an anticancer agent. As a result, it is possible to react various types or concentrations of anticancer drugs to specific cancer patient cells in a single experiment, so that a customized prescription is possible for each cancer patient.

Hereinafter, with reference to FIGS. 2 and 3, a process of inducing a reaction between a specimen and a drug in the reaction chamber unit 100 will be described in detail.

FIG. 2 is an enlarged plan view showing a part of the drug reactivity testing device of FIG. 1, and FIG. 3 is a cross-sectional view taken along line III-III' of FIG. 2. In addition, Figure 4 is a plan view schematically showing a drug reactivity test apparatus according to another embodiment of the present invention.

First, referring to FIGS. 2 and 3, a sample C is accommodated in the cavity 101 of the reaction chamber unit 100 of the drug reactivity test apparatus according to an embodiment of the present invention, and the sample C and The reacting drug is a reaction chamber unit through a plurality of micro-channels 210, 220, 230, 240, 250 shown in FIG. 1, specifically, a plurality of reaction flow channels 211, 221, 231, 241, 251 It is transferred to 100. At this time, the plurality of reaction flow paths 211, 221, 231, 241, 251 are at least a part of the plurality of micro flow paths 210, 220, 230, 240, 250 and are located directly under the reaction chamber unit 100. It is a part as described above. For reference, the arrows shown in FIGS. 2 and 3 indicate the flow direction of the drug.

In one embodiment, the specimen (C) may be a cancer cell that is a patient-derived cell, and the drug reacting with the specimen (C) may include an anticancer agent.

As shown in FIG. 2, a plurality of reaction flow paths 211, 221, 231, 241 and 251 are disposed to be spaced apart from each other under the cavity 101. At this time, the plurality of reaction flow paths 211, 221, 231, 241, 251 are disposed across the cavity 101. For example, when the shape of the cavity 101 is rectangular, the plurality of reaction flow paths 211, The 221, 231, 241, and 251 may extend in a direction perpendicular to the long side of the cavity 101.

In one embodiment, different types of drugs may be transported through each of the plurality of reaction flow paths 211, 221, 231, 241, and 251. That is, a drug flowing through at least one of the plurality of reaction passages 211, 221, 231, 241, and 251 may be different from a drug flowing through the other passages. As another example, the types of drugs flowing in each of the plurality of reaction flow paths 211, 221, 231, 241, and 251 may be all different. In this case, the type of drug that can be tested corresponds to the number of the plurality of reaction channels 211, 221, 231, 241, 251.

For example, a first drug flowing in the first micro-channel 211, which is one of the plurality of reaction flow channels 211, 221, 231, 241, 251, and a second micro-channel neighboring the first micro-channel 211 The second drug flowing through the flow path 221 may have different types.

In another embodiment, drugs having the same type but different concentrations may be transported through each of the plurality of reaction passages 211, 221, 231, 241, and 251. That is, a drug flowing through at least one of the plurality of reaction passages 211, 221, 231, 241, and 251 may have the same type as the drug flowing through the other passages, but may have different concentrations. As another example, the concentrations of the drug flowing for each of the plurality of reaction flow paths 211, 221, 231, 241, and 251 may all be different. In this case, the concentration of the drug that can be tested corresponds to the number of the plurality of reaction flow paths 211, 221, 231, 241, 251.

For example, a first drug flowing in the first micro-channel 211, which is one of the plurality of reaction flow channels 211, 221, 231, 241, 251, and a second micro-channel neighboring the first micro-channel 211 The second drugs flowing through the flow path 221 may have different concentrations even if they are of the same type.

As described above, the reactivity can be tested under various experimental conditions by varying the type and concentration of the drug for one sample through the plurality of reaction channels 211, 221, 231, 241, 251. In addition, by injecting drugs into each of the plurality of reaction channels 211, 221, 231, 241, and 251 at the same time, it is possible to quickly test the reactivity of several drugs with respect to a sample.

As shown in FIG. 3, the transmission part 300 is interposed between the plurality of reaction flow paths 211, 221, 231, 241, 251 and the specimen C accommodated in the cavity 101. The permeable part 300 is a part that penetrates the drug flowing inside the plurality of reaction flow paths 211, 221, 231, 241, 251 toward the specimen C, and is transferred to the specimen C through the permeable portion 300. The drug reacts with the sample (C).

At least a part of the plurality of reaction flow paths 211, 221, 231, 241, 251 is hollow so that the drug can be delivered to the sample C from the plurality of reaction flow paths 211, 221, 231, 241, 251 It can be opened to the part 101. At this time, in the lower region of the cavity 101, the first reaction flow path 211, the second reaction flow path 221, the third reaction flow path 231, the fourth reaction flow path 241, and the fifth reaction flow path 251 When the correspondingly divided regions are referred to as the first reaction region 110a, the second reaction region 120a, the third reaction region 130a, the fourth reaction region 140a, and the fifth reaction region 150a, the first The transmission part 300 is positioned below the fifth to fifth reaction regions 110a, 120a, 130a, 140a, and 150a. Accordingly, the reaction regions 110a, 120a, 130a, 140a, and 150a may be defined as regions in which a reaction between the specimen C and the drug occurs.

In one embodiment, the transmission part 300 crosses all of the first to fifth reaction regions 110a, 120a, 130a, 140a, 150a, and a plurality of reaction flow paths 211, 221, 231, 241, 251 The cavity 101 may be disposed in the abutting portion. That is, the size of the transmission part 300 substantially corresponds to the total size of the lower region of the cavity part 101.

The drug introduced into the plurality of flow paths 211, 221, 231, 241, 251 may diffuse toward the sample C located above the plurality of reaction flow paths 211, 221, 231, 241, 251, At this time, the penetration part 300 slowly diffuses a part of the drug, thereby appropriately controlling the amount of drug diffusion and limiting the position of the drug diffusion to a predetermined area.

Specifically, a part of the drug flowing through the first to fifth reaction channels 211, 221, 231, 241, 251 is diffused toward the specimen C through the transmission part 300, so that a part of the drug is in the cavity ( 101) of the first to fifth reaction regions 110a, 120a, 130a, 140a, 150a, respectively, can be guided with high accuracy, and the guided amount can also be appropriately adjusted so as not to invade the neighboring reaction regions. I can. That is, the permeable part 300 serves to control the direction and flow rate in which the drug introduced into the plurality of flow paths 211, 221, 231, 241, 251 is diffused.

For this, the permeable part 300 may have a fine hole or may be formed in a mesh structure, and in one embodiment, the permeable part 300 may include a membrane.

A cover part 400 may be disposed on the transmission part 300. The cover part 400 is located in the cavity 101 of the reaction chamber part 100, and covers the sample C and the transmission part 300 together and serves to seat the sample C on the transmission part 300. . As a result, it is possible to properly (half) fix the sample (C) in the cavity 101 during the test so that it does not disperse unevenly or some cells of the sample (C) are swollen to one side, and the cells responding to one type of drug can be They can move towards cells that have responded to other types of drugs and prevent problems with poor testing.

The cover part 400 may have adhesiveness so that the specimen (C) can be easily seated. For example, the cover part 400 has a gel state on the specimen (C) and the permeable part (300). It can be formed in a form applied to. Of course, the present invention is not limited thereto, and the cover part 400 may be formed in the form of a coating layer or a film including a material having adhesive properties.

In one embodiment, the cover part 400 may include an extracellular matrix (ECM) mimicking material. By using a cell-friendly material as a material for the cover part 400 as described above, contamination and damage of the specimen C placed under the cover part 400 can be minimized.

Since the above-described transmission part 300 and the cover part 400 are provided, the drug reactivity test apparatus according to an embodiment of the present invention can independently deliver drugs to various regions of a sample C.

Next, referring to FIG. 4, the drug reactivity test apparatus according to another embodiment of the present invention illustrated in FIG. 4 is performed as described above with reference to FIGS. 2 and 3 except for the shape and position of the transmission part 300. The same or similar to the examples and their modifications. Therefore, the description of the other configurations other than the transmission part 300 is replaced or abbreviated as the above, and will be described below with the focus on the structure of the transmission part 300.

Corresponding to the first reaction passage 211, the second reaction passage 221, the third reaction passage 231, the fourth reaction passage 241 and the fifth reaction passage 251 in the lower region of the cavity 101 The divided regions are referred to as the first reaction region 110a, the second reaction region 120a, the third reaction region 130a, the fourth reaction region 140a, and the fifth reaction region 150a. The transmission part 300 is positioned below the fifth to fifth reaction regions 110a, 120a, 130a, 140a, and 150a.

At this time, the transmission part 300 includes a plurality of individual transmission parts 310, 320, 330, 340, 350, ??), and each of the plurality of individual transmission parts 310, 320, 330, 340, 350, ??) It may be disposed below the first to fifth reaction regions 110a, 120a, 130a, 140a, and 150a.

Specifically, the plurality of individual transmission portions 310, 320, 330, 340, and 350 are disposed to be spaced apart from each other, and the first reaction region 110a, the second reaction region 120a, the third reaction region 130a, Each of the fourth and fifth reaction regions 140a and 150a includes a first transmission part 310, a second transmission part 320, a third transmission part 330, a fourth transmission part 340, and a fifth transmission part 350. ) Is placed.

That is, unlike the above-described embodiment, the size of the transmission part 300 in this embodiment is not the entire size of the lower region of the cavity 101, but the first to fifth reaction regions 110a, 120a, 130a, 140a, 150a. It will correspond to the size. In this way, even if the size of the transmission part 300 is smaller than that of the above-described embodiment, the plurality of individual transmission parts 310, 320, 330, 340, and 350 constituting the transmission part 300 are the first to fifth reaction regions. Since it is arranged to correspond to (110a, 120a, 130a, 140a, 150a), the present embodiment also provides an appropriate amount of drug with high accuracy in each of the first to fifth reaction regions 110a, 120a, 130a, 140a, 150a. I can guide you.

Accordingly, the drug reactivity test apparatus according to another embodiment of the present invention can also deliver drugs independently to multiple regions of one specimen (C).

5 is an image showing a result of injecting a dye into a drug reactivity testing device according to an embodiment of the present invention, and FIG. 6 is an image showing a result of injecting a drug into a drug reactivity testing device according to an embodiment of the present invention to be.

First, FIG. 5 is a result of an experiment in which a blue dye and a green dye are alternately injected into a plurality of microchannels of a drug reactivity test apparatus according to an embodiment of the present invention.

Specifically, the blue dye is Hoechst at a concentration of 5 μM, and the green dye is Cell tracker at a concentration of 5 μM? green, and 60 μL of the blue dye and the green dye were injected into each microchannel. At this time, the number of cells accommodated in the reaction chamber was about 5x10 ⁴ , and the dye was injected into the microchannels while the cells were properly dispersed and seated on each of the microchannels.

For reference, the width, depth, and length of each of the microchannels are 160 μm, 200 μm and 5000 μm, and a track-etch type PET membrane was used as the transmission part, and the porosity of the transmission part Was 4x10 ⁶ /cm ² .

As a result of the above experiment, it can be seen that, as shown in FIG. 5, a green area and a blue area are clearly distinguished among a plurality of areas spaced apart from each other. In this case, the plurality of regions spaced apart from each other correspond to the reaction regions in which the reaction between the specimen and the drug occurs in the actual drug reactivity test.

In this way, when the blue area into which the blue dye is introduced and the green area into which the green dye is introduced are separated from each other, drug interference with neighboring reaction areas hardly occurs, and the drug introduced into one reaction channel is It can be interpreted that the transmission is limited to only the reaction region located directly above the reaction flow path.

Next, FIG. 6 is a result of an experiment in which doxorubicin, an anticancer agent, is reacted to breast cancer cells (MCF7) using the drug reactivity test apparatus according to an embodiment of the present invention.

Specifically, a breast cancer cell as a sample was placed in the reaction chamber, and 60 μL of the drug doxorubicin was continuously flowed into the plurality of microchannels for 2 days, and the blue dye and the blue dye as in FIG. Using a green dye, the samples before the reaction were stained green and the samples after the reaction were stained blue. At this time, the number of responding cells was about 5x10 ⁴ as in the experiment of FIG. 5, and the specifications of the microchannel and the material and specifications of the permeable part were also the same as those used in the experiment of FIG. 5.

As a result of the above experiment, it can be seen that the ratio of green and blue is different for each of the regions as shown in FIG. 6. At this time, each of the regions refers to the reaction regions in which the reaction between the sample and the drug occurs, and the leftmost is an image of the reaction region formed on the flow path where the drug is not introduced, and the second from the left is the drug with a concentration of 20 μM. The image of the reaction area formed on the flow path, the third from the left is the image of the reaction area formed on the flow path into which the drug having a concentration of 200 μM was introduced, and the rightmost is the image of the reaction area formed on the flow channel into which the drug having a concentration of 2000 μM was introduced This is an image of the reaction area.

Therefore, the fact that the proportion of green in the reaction region is inversely proportional to the concentration of the drug as in the image of FIG. 6 changes the degree of reaction between the sample and the drug in the reaction region according to the concentration of the drug, and this is also in one reaction channel. This is a result of the delivery of the introduced drug by being limited to the reaction region located directly above the reaction flow path.

That is, when using the drug reactivity test apparatus according to an embodiment of the present invention, as shown in FIGS. 5 and 6, test results obtained by different types and concentrations of drugs can be checked at a time.

As described above, the drug reactivity test apparatus according to an embodiment of the present invention may simultaneously test the reactivity of a specimen with respect to various drugs. In addition, a relatively small number of cells can be tested without a cell proliferation process, and a decrease in cell viability can be minimized through rapid testing. As a result, it is possible to easily perform reactivity tests of patient-derived cells, etc., whose cellular activity is rapidly decreasing, thereby enabling customized drug prescription for each patient.

As described above, the present invention has been described with reference to an embodiment shown in the drawings, but this is only illustrative, and it will be understood by those of ordinary skill in the art that various modifications and variations of the embodiment are possible therefrom. . Therefore, the true technical protection scope of the present invention should be determined by the technical spirit of the appended claims.

10: drug reactivity test device
80: inlet chamber part
81, 82, 83, 84, 85: first to fifth inlet chamber portions
90: exhaust chamber pain reduction system
100: reaction chamber part
101: cavity
110a, 120a, 130a, 140a, 150a: first to fifth reaction zones
210, 220, 230, 240, 250: first to fifth microchannels
211, 221, 231, 241, 251: first to fifth connection flow paths
212, 222, 232, 242, 252: first to fifth reaction channels
300: transmission part
310, 320, 330, 340, 350: first to fifth transmission parts
400: cover part
C: specimen

Claims (15)

A reaction chamber portion having a cavity portion for accommodating a specimen;
A plurality of microchannels disposed to be spaced apart from each other under the cavity and transferring drugs reacting with the specimen; And
A transmission part interposed between the sample and the plurality of microchannels to transmit the drug toward the sample; and
The drug reactivity test apparatus, wherein the transmission part delivers the drug to regions partitioned corresponding to each of the plurality of microchannels of the cavity. The method of claim 1,
A drug reactivity test apparatus further comprising a; cover portion disposed to cover the specimen and the transmission portion in the cavity portion. The method of claim 2,
The cover part includes an extracellular matrix (ECM) mimicking material. The method of claim 1,
The drug reactivity test apparatus further comprising; an inflow chamber part for introducing the drug into the plurality of microchannels. The method of claim 4,
The inflow chamber unit includes a plurality of individual chamber units connected to each of the plurality of microchannels. The method of claim 1,
A drug reactivity test apparatus further comprising a; discharge chamber part for discharging the drug from the plurality of micro-channels. The method of claim 1,
The plurality of micro-channels include a first micro-channel and a second micro-channel,
The drug reactivity test apparatus, wherein the first drug transported through the first microchannel is different from that of the second drug transported through the second microchannel. The method of claim 1,
The plurality of micro-channels include a first micro-channel and a second micro-channel,
The drug reactivity test apparatus, wherein the first drug transported through the first microchannel has a different concentration than the second drug transported through the second microchannel. The method of claim 1,
Each of the plurality of micro-channels has the same length and width, the drug reactivity test apparatus. The method of claim 1,
Each of the plurality of micro-channels simultaneously transports the drug, a drug reactivity test apparatus. delete The method of claim 1,
The permeable portion includes a plurality of individual permeable portions for delivering the drug to each of the divided regions. The method of claim 1,
The permeable portion includes a membrane for partially passing the drug through the plurality of microchannels. The method of claim 1,
The test device for drug reactivity, wherein the specimen contains cells. The method of claim 1,
The drug is a drug reactivity test device comprising an anticancer agent.

Images